Ann: Investor Presentation - 1H FY21 Results, page-6

ha, agree mainly but their target is still $2.48 which is not too shabby from here.

I keep adding to IME when I have opportunity and really could care less about the short term noise / company aquisition or even if they miss CF+ this year amd need a $5m top up raise.

to me it’s all about Aquila in the cloud ARR and the other launching verticals in pathology / vet / dental imaging. This is the Xero cloud platform model for radiology and they added 700K ARR last qtr alone. If they stayed at the same rate they would be adding $2.8m ARR a year but their growth is going to continue exponentially as both the Aquila pipeline continues to deepen and other verticals come online and start building their own pipelines. I can see them adding $5m ARR 2022 and $7m 2023 very realistically.

in 2 years I have no doubt they will be CF+ and over $20m ARR even without any other big contracts. With some major wins it’s not hard to see upside to that either.

to me from current $42m market cap this is very capable of 3-5 bags the next 2 years for the patient investor who doesn’t expect to make money overnight